Metastasis News and Research RSS Feed - Metastasis News and Research

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases
Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. [More]
Inflammation in tissue creates a niche for cancer cells

Inflammation in tissue creates a niche for cancer cells

In order to invade healthy tissue, tumor cells must leave the actual tumor and enter the bloodstream or lymphatic system. For this purpose, they use certain enzymes, proteases that break down the tissue surrounding the tumor, thus opening the way for tumor cells to reach blood or lymphatic vessels. To keep the proteases in check, the body produces inhibitors such as the protein TIMP-1, which thwart the proteases in their work. [More]
Blocking STAT3 in immune system cells increases anti-tumour immunity

Blocking STAT3 in immune system cells increases anti-tumour immunity

The STAT transcription factors are involved in the development of many forms of cancer. STAT3 is frequently activated in tumour cells, so drugs targeting STAT3 could be used in cancer therapy. However, STAT3 is also important in the development of the immune system. Dagmar Gotthardt and colleagues at the Vetmeduni Vienna now show that blocking STAT3 in cells of the immune system actually leads to increased anti-tumour immunity. Anti-STAT3 therapy may thus be highly promising. [More]
BCRF announces $58.6 million commitment to breast cancer research

BCRF announces $58.6 million commitment to breast cancer research

The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research. [More]
GenomOncology, med fusion partner to optimize treatment strategies for tumor

GenomOncology, med fusion partner to optimize treatment strategies for tumor

med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient's disease state and tumor profile. [More]
Researchers discover novel mechanisms of cell migration

Researchers discover novel mechanisms of cell migration

During cancer metastasis, immune response or the development of organisms, cells are moving in a controlled manner through the body. Researchers from the Department of Biomedicine at the University of Basel discovered novel mechanisms of cell migration by observing cells moving on lines of connective tissue. [More]
Delta Air Lines kicks off annual campaign to promote awareness on breast cancer

Delta Air Lines kicks off annual campaign to promote awareness on breast cancer

Delta Air Lines' (NYSE: DAL) annual "Breast Cancer One" employee survivor flight took place yesterday, kicking off the airline's month-long campaign to generate awareness and raise money for The Breast Cancer Research Foundation. [More]
Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher. [More]
ANN expands commitment to BCRF through annual Breast Cancer Awareness campaign

ANN expands commitment to BCRF through annual Breast Cancer Awareness campaign

ANN INC., the parent Company of Ann Taylor and LOFT, today announces its expanded commitment to The Breast Cancer Research Foundation through its annual Breast Cancer Awareness campaign and latest in-store and online promotions. [More]
Alectinib promise for crizotinib-resistant NSCLC

Alectinib promise for crizotinib-resistant NSCLC

Alectinib has shown promising antitumour activity in patients with ALK-rearranged non-small-cell lung cancer that is resistant to crizotinib, researchers report. [More]
Blocking AEG-1 gene expression halts development of liver cancer by regulating inflammation

Blocking AEG-1 gene expression halts development of liver cancer by regulating inflammation

Inflammation has been shown to be a driving force behind many chronic diseases, especially liver cancer, which often develops due to chronic inflammation caused by conditions such as viral hepatitis or alcoholism and has relatively few effective treatment options. [More]
Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

EKF Diagnostics, the global diagnostics company, announces that it has entered into a two year research collaboration with Massachusetts General Hospital (MGH), a global leader in successfully bridging innovative science with state-of-the-art clinical medicine, to develop PointMan™ assays that can effectively detect treatable cancer mutations in blood samples. [More]
Research findings provide avenue for targeted therapy to treat AML

Research findings provide avenue for targeted therapy to treat AML

A novel study by the Cancer Science Institute of Singapore at the National University of Singapore found that an increase in a gene known as Leo1 affects other genes that are directly implicated in acute myelogenous leukaemia (AML), increasing the incidence of cancer. [More]
Distinct patterns of gene expression identified in several groups of pancreatic CTCs

Distinct patterns of gene expression identified in several groups of pancreatic CTCs

Analysis of circulating tumor cells (CTCs) in a mouse model of pancreatic cancer identified distinct patterns of gene expression in several groups of CTCs, including significant differences from the primary tumor that may contribute to the ability to generate metastases. [More]
Immature blood vessels linked to poor sunitinib response

Immature blood vessels linked to poor sunitinib response

Patients with clear-cell renal cell carcinoma with relatively mature blood vessels respond better to sunitinib and have fewer metastatic sites than those with immature vessels, a study has found. [More]
Researchers develop protein therapy that may stop cancer growth

Researchers develop protein therapy that may stop cancer growth

A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body. [More]
New approach to imaging metastatic tumors

New approach to imaging metastatic tumors

Bioluminescence, nanoparticles, gene manipulation - these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors. [More]
Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Treatment with endocrine therapy and radiation therapy as part of breast conservation is the current standard of care for women with hormone-receptor positive (HR+) invasive breast cancer. A new study by researchers at Fox Chase Cancer Center, however, shows that combination may not be necessary for all patient populations with the disease. [More]
UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults. [More]
Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. [More]